Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Known hypersensitivity to any of the study drugs.
• •History of other malignancy that could affect compliance with the protocol or interpretation of the results.
• •Has a diagnosis of immunodeficiency excluding human immunodeficiency virus (HIV) infection or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Subjects may use topical or inhaled corticosteroids or low-dose steroids (=\< 10 mg of prednisone or equivalent per day) as therapy for comorbid conditions. During study participation, subjects may receive systemic or enteric corticosteroids as needed for treatment-emergent comorbid conditions.
• •Has a known history of active TB (Bacillus tuberculosis).
• •Prior systemic chemotherapy for lymphoma with the exception of corticosteroids for palliation of symptoms and patients with prior indolent non-Hodgkin lymphoma (NHL) treated with single agent rituximab.
• •Has known active central nervous system (CNS) lymphoma.
• •Richter?s transformation from chronic lymphocytic leukemia (CLL).
• •Major surgery within 3 weeks prior to start of study treatment.
• •Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Conditions expected to not recur in the absence of an external trigger.
• •Has an active infection requiring intravenous systemic therapy or uncontrolled systemic infection including viral, bacterial, or fungal.
• •Is unable to swallow capsules or malabsorption syndrome, disease or condition significantly affecting gastrointestinal function.
• •Clinically significant cardiovascular disease, including uncontrolled arrhythmia, New York Association class 2- 4 congestive heart failure, or history of myocardial infarction within 6 months.
• •Known contraindication to any medication in the treatment plan, including clinically significant peripheral neuropathy.
• •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
• •Female patients who are not surgically sterile or postmenopausal (for at least 1 year) must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 5 months after study treatment:
• •* Total abstinence from hetero-sexual intercourse
• •* A vasectomized partner
• •* Hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) that started at least 3 months prior to study drug administration
• •* Double-barrier method (condom + diaphragm or cervical cup with spermicidal contraceptive sponge, jellies, or cream)
• •* Non-vasectomized male patients must comply with at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:
• •* A partner who is surgically sterile or postmenopausal (for at least 1 year) or who is taking hormonal contraceptives (oral, parenteral, vaginal ring, or transdermal) for at least 3 months prior to study drug administration
• •* Total abstinence from hetero-sexual intercourse
• •* Double-barrier method (condom + diaphragm or cervical cup with spermicidal, contraceptive sponge, jellies, or cream).
• •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
• •Acute hepatitis C (defined as positive hepatitis C virus (HCV) ribonucleic acid (RNA) \[qualitative\] and diagnosis within the past 6 months).
• •Positive hepatitis C antibody with evidence of cirrhosis.
• •Active hepatitis B (subjects with a positive hepatitis B virus \[HBV\] core antibody or surface antigen are eligible as long as they have an undetectable HBV DNA polymerase chain reaction \[PCR\] and receive concurrent antiviral therapy with entecavir or tenofovir, and continued for a minimum of 6 months after completion of therapy).
• •HIV infection AND CD4 count \< 100 cells/ mm\^3, evidence of resistant strain of HIV, or HIV viral load \>= 50 copies HIV RNA/mL if on highly active antiretroviral therapy (HAART) or HIV viral load \>= 10,000 copies HIV RNA/mL if not on anti-HIV therapy.